Role du microbiote intestinal et avec anticorps anti-PD1 induit immunesurveillance du cancer du rein

Role du microbiote intestinal et avec anticorps anti-PD1 induit immunesurveillance du cancer du rein

Les cancers du rein métastatiques résistants aux inhibiteurs de tyrosine kinase peuvent faire l’objet de traitements fondés sur le blocage des points de contrôles immunitaires (ICB). Cependant, les ICB induisent des réponses chez une minorité de patients, et des efforts sont en cours pour identifier...

Full description

Bibliographic Details
Main Author:	Derosa, Lisa
Other Authors:	Paris Saclay
Language:	fr
Published:	2019
Subjects:	Microbiote Anticorps anti-PD1 Cancer du rein Flore intestinal Nivolumab Gut microbiota Anti-PD1 therapy Kidney cancers Rcc
Online Access:	http://www.theses.fr/2019SACLS175

Similar Items

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
by: Andrea Botticelli, et al.
Published: (2018-08-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Étude de l'endocytose du récepteur PD-1 dans les lymphocytes T humains
by: Ben Saad, Elham
Published: (2020)

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
by: Edouard Chasseuil, et al.
Published: (2018-01-01)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
by: Emeric Limagne, et al.
Published: (2019-04-01)

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
by: Qingyuan Huang, et al.
Published: (2018-12-01)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
by: Giandomenico Roviello, et al.
Published: (2020-01-01)

Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?
by: Kong X, et al.
Published: (2017-03-01)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
by: Oliver Klein, et al.
Published: (2021-01-01)

Immunotherapy for Gastroesophageal Cancer
by: Emily F. Goode, et al.
Published: (2016-09-01)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018-01-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor
by: Kimihiro Shimatani, et al.
Published: (2018-03-01)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
by: Paolo A. Ascierto, et al.
Published: (2019-03-01)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
by: Michael Lattanzi, et al.
Published: (2018-10-01)

Biomarkers for immunotherapy in bladder cancer: a moving target
by: David H. Aggen, et al.
Published: (2017-11-01)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017-10-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Fundamental effects of PD-1 antibody on the body: a brief report
by: Wang W, et al.
Published: (2016-07-01)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
by: Aixa E. Soyano, et al.
Published: (2018-11-01)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
by: Dean A. Fennell, et al.
Published: (2018-04-01)

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
by: Ning Lyu, et al.
Published: (2020-10-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
by: Ryota Shibaki, et al.
Published: (2019-04-01)

Use of nivolumab for colon cancer with Lynch syndrome
by: G. A. Khakimov, et al.
Published: (2020-11-01)

The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
by: Joseph DiDomenico, et al.
Published: (2018-07-01)

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
by: Bingxin Zheng, et al.
Published: (2018-02-01)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
by: Gou M, et al.
Published: (2019-01-01)

5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients
by: Min Zhang, et al.
Published: (2020-04-01)

Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
by: Ryuichi Saito, et al.
Published: (2021-02-01)

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
by: Hui Zhou, et al.
Published: (2019-05-01)

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
by: Bernhard Roither, et al.
Published: (2020-12-01)

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
by: Li B, et al.
Published: (2018-06-01)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
by: Wagner LM, et al.
Published: (2017-04-01)

Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report
by: Qiu ZX, et al.
Published: (2019-10-01)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
by: Daan P. Hurkmans, et al.
Published: (2019-07-01)

Cannot write session to /tmp/vufind_sessions/sess_cmgrida314k5burtpe0d390427